Drugs / HTC-867
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00827489 | Jan → Apr 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01268124 | Dec 2008 → Apr 2009 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTC-867 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01268124 ↗ |
| Route | Oral | “single oral doses of HTC-867” NCT00827489 ↗ |